Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OSE-127
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 11, 2021
Lead Product(s) : OSE-127
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OSE-127
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 10, 2019
Lead Product(s) : OSE-127
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable